We are excited to share the publication of the first-in-human clinical studyof COVAC-2, a recombinant protein subunit vaccine against COVID-19 formulated with Sepivac SWE™, an oil-in-water adjuvant co-developed by VFI and Seppic. Led by our long-standing partner Vaccine and Infectious Disease Organization (VIDO), the study confirms that the Sepivac SWE™-adjuvanted vaccine is safe and induces robust neutralizing antibody responses across age groups.
Read the article.
VFI is pleased to pursue its collaboration with TBVAC in the pursuit of a safe and effective vaccine against tuberculosis. VFI will provide adjuvants and formulation expertise to accelerate the development of TBVAC's promising vaccine candidates, and to advance towards a world without tuberculosis. The VFI team is proud to be part of this crucial effort and look forward to the positive impact our work will have on public health.
For News release read here
The Vaccine Formulation Institute (VFI) and the Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan (USask) have signed a collaborative research agreement to help drive joint vaccine development.
Read press release here.
ISIDORe - “Integrated Services for Infectious Disease Outbreak Research”, has been officially launched on 24 February 2022. This 21M€ EU-funded large-scale project assembles an unprecedented One Health-driven, integrated portfolio of cutting-edge research services and resources, dedicated to the study of epidemic-prone diseases including SARS-CoV-2 variants. VFI offers a range of TransNational Access Services on adjuvants and formulation expertise in order to fight epidemic diseases.
For Press release read here
VFI is pleased to announce its continued partnership with VIDO, thanks to a 5M USD award from CEPI (Coalition of Epidemics Preparedness Innovations), to develop new vaccines that are broadly protective against COVID-19 variants and suitable for use in Low- and Middle-Income Countries. This work builds on the development of COVAC-2, VIDO’s subunit vaccine formulated with Sepivac SWE™, an adjuvant co-developed by Seppic and VFI.
Click here to read VIDO press release and CEPI press release
